加斯特罗丁通过抑制PAK2酸化来改善糖尿病患者的认知功能障碍
Zhi-Hao Mu1, Zhi-Min Zhao1,2, Su-Su Yang1,3
1Department of Pathology and Pathophysiology, Faculty of Basic Medical Sciences, Kunming Medical University, Kunming, China.
Aging
|August 23, 2023
概括
这项研究表明,糖尿病会损害老鼠的空间学习和记忆. 加斯特罗丁治疗改善了认知功能和神经元健康,突出了PAK2通路作为潜在的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病与增加的认知功能障碍有关.
- 驱动糖尿病相关认知衰退的确切机制尚不清楚.
- 确定治疗点对于管理这种情况至关重要.
研究的目的:
- 调查糖尿病引起的认知功能障碍背后的机制.
- 评估Gastrodin在缓解这些缺陷方面的治疗潜力.
- 探索特定分子通路在糖尿病相关认知障碍中的作用.
主要方法:
- 在老鼠模型中使用链毒素诱导糖尿病.
- 通过莫里斯水迷宫测试来评估空间学习和记忆.
- 转录学,西方污点和免疫光学被用来分析分子变化.
主要成果:
- 糖尿病老鼠表现出空间学习障碍和海马神经元损伤.
- 加斯特罗丁的使用逆转了认知缺陷,并减少了神经元损伤.
- 转录组学发现了差异性基因表达,涉及到p21激活激酶2 (PAK2) 途径在海马损伤.
结论:
- PAK2通路在糖尿病引起的认知功能障碍中起着重要作用.
- 通过向PAK2通路,Gastrodin证明了治疗疗效.
- 抑制PAK2可能为糖尿病认知障碍提供一种新的治疗策略.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
GPCRs Regulate Adenylyl Cylase Activity
5.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
205
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
205
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
392
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
392


